Screener
Xeris Biopharma Holdings, Inc. XERS Gvoke — Product revenue, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product revenue: | ||||
| Recorlev | $56,780 | $31,444 | $106,548 | $56,974 |
| Gvoke | 22,549 | 23,467 | 43,349 | 44,312 |
| Keveyis | 11,675 | 11,485 | 23,561 | 22,912 |
| Other product revenue | — | 1,312 | — | 1,312 |
| Product revenue, net | 91,004 | 67,708 | 173,458 | 125,510 |
| Royalty, contract and other revenue | 1,096 | 3,831 | 1,769 | 6,148 |
| Total revenue | $92,100 | $71,539 | $175,227 | $131,658 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s gvoke — product revenue, net?
- Xeris Biopharma Holdings, Inc. (XERS) reported gvoke — product revenue, net of $22.55M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s gvoke — product revenue, net changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s gvoke — product revenue, net decreased by 3.9% year-over-year, from $23.47M to $22.55M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s gvoke — product revenue, net?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s gvoke — product revenue, net has grown at a 24.7% compound annual growth rate (CAGR), from $38.92M to $94.11M.
- What does gvoke — product revenue, net mean?
- This metric represents the total net sales generated from the specific pharmaceutical product line after accounting for returns, rebates, and other sales deductions. It serves as a primary indicator of market adoption, commercial success, and the underlying demand for the therapy within its therapeutic category. Tracking this revenue stream helps investors assess the product's growth trajectory and its contribution to the company's overall top-line performance.
Ask your AI about Xeris Biopharma Holdings, Inc.'s gvoke — product revenue, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude